Positive Health Online
Your Country
Research: THOMPSON and COLLEAGUES,
Listed in Issue 232
Abstract
THOMPSON and COLLEAGUES, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, Mail Code 8026, 7979 Wurzbach, Suite 627, Zeller Building, San Antonio, TX 78229, USA review clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and discuss future prevention direction.
Background
The high global incidence of prostate cancer has led to a focus on chemoprevention strategies to reduce the public health impact of the disease.
Methodology
Early studies indicating that selenium and vitamin E might protect against prostate cancer encouraged large-scale studies that produced mixed clinical results.
Results
Next-generation prostate cancer prevention trials validated the impact of 5α-reductase inhibitors in hormone-responsive prostate cancer, and these results were confirmed in follow-up studies. Other interventions on the horizon, involving both dietary and pharmacological agents, hold some promise but require further investigation to validate their efficacy.
Conclusion
In this Review, we discuss the clinical and preclinical evidence for dietary and pharmacological prevention of prostate cancer and give an overview of future opportunities for chemoprevention.
References
Thompson IM Jr, Cabang AB, Wargovich MJ. Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol 11(1):49-60. doi: 10.1038/nrclinonc.2013.211. Epub Nov 26 2013. Jan 2014.